KLRAKailera Therapeutics Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pi…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives. | ||
 Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? Kailera Therapeutics (KLRA) is in focus after reporting a second quarter net loss of US$111.31 million and a six month net loss of US$190.17 million, alongside the appointment of Nur Nicholson as Chief Technology Officer. See our latest analysis for Kailera Therapeutics. The recent earnings update and leadership change come against a weaker backdrop for Kailera Therapeutics, with the share price at US$17.94 and the year to date share price return down 31%, suggesting momentum has been... | ||
 2 GLP-1 Stocks That Could Double Your Money by 2031 They are fairly risky, but their potential upside is massive. | ||
 2 Beaten-Down GLP-1 Stocks to Buy on the Dip Don't wait until clinical milestones send their share prices soaring. | ||
IInsider Monkey | ||
MMT Newswires | ||
MMT Newswires | ||